CA3049608A1 - Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof - Google Patents
Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof Download PDFInfo
- Publication number
- CA3049608A1 CA3049608A1 CA3049608A CA3049608A CA3049608A1 CA 3049608 A1 CA3049608 A1 CA 3049608A1 CA 3049608 A CA3049608 A CA 3049608A CA 3049608 A CA3049608 A CA 3049608A CA 3049608 A1 CA3049608 A1 CA 3049608A1
- Authority
- CA
- Canada
- Prior art keywords
- triazolo
- amine
- quinoxalin
- phenyl
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710014520 | 2017-01-09 | ||
| CN201710014520.1 | 2017-01-09 | ||
| PCT/CN2018/071851 WO2018127195A1 (zh) | 2017-01-09 | 2018-01-09 | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3049608A1 true CA3049608A1 (en) | 2018-07-12 |
Family
ID=62789082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3049608A Pending CA3049608A1 (en) | 2017-01-09 | 2018-01-09 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10874670B2 (enExample) |
| EP (1) | EP3567041B1 (enExample) |
| JP (1) | JP7247092B2 (enExample) |
| KR (1) | KR102660196B1 (enExample) |
| CN (1) | CN110167941B (enExample) |
| AU (1) | AU2018206111B2 (enExample) |
| CA (1) | CA3049608A1 (enExample) |
| WO (1) | WO2018127195A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221020T1 (hr) | 2018-07-20 | 2022-11-11 | Grünenthal GmbH | Supstituirani derivati triazolo kinoksalina |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| WO2021004482A1 (zh) * | 2019-07-10 | 2021-01-14 | 上海瑛派药业有限公司 | 取代的吡唑并喹唑啉酮化合物及其应用 |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| EP4028400A4 (en) | 2019-09-12 | 2023-09-06 | Impact Therapeutics (Shanghai), Inc | Substituted imidazoquinoxaline compounds and uses thereof |
| EP4084495A4 (en) | 2020-04-29 | 2023-07-12 | Shenzhen Shokz Co., Ltd. | ACOUSTIC DEVICE, AND CORRESPONDING MAGNETIC CIRCUIT ASSEMBLY |
| KR102458689B1 (ko) * | 2020-07-08 | 2022-10-25 | 원광대학교산학협력단 | 피페리딘 화합물 및 이의 제조 방법 |
| AU2022264775A1 (en) * | 2021-04-26 | 2023-11-09 | Ohio State Innovation Foundation | Lipid nanomaterials and uses thereof |
| JP2026504889A (ja) * | 2023-01-18 | 2026-02-10 | アンテンジーン・ディスカバリー・リミテッド | Ｐｒｍｔ５阻害化合物およびその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| EP2303890A4 (en) * | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| DE102010025786A1 (de) | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
| CA2810708A1 (en) * | 2010-09-16 | 2012-03-22 | Hutchison Medipharma Limited | Fused heteroaryls and their uses |
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| NO2714752T3 (enExample) * | 2014-05-08 | 2018-04-21 |
-
2018
- 2018-01-09 US US16/476,762 patent/US10874670B2/en active Active
- 2018-01-09 WO PCT/CN2018/071851 patent/WO2018127195A1/zh not_active Ceased
- 2018-01-09 CN CN201880006343.5A patent/CN110167941B/zh active Active
- 2018-01-09 JP JP2019537063A patent/JP7247092B2/ja active Active
- 2018-01-09 AU AU2018206111A patent/AU2018206111B2/en active Active
- 2018-01-09 EP EP18735878.3A patent/EP3567041B1/en active Active
- 2018-01-09 KR KR1020197023280A patent/KR102660196B1/ko active Active
- 2018-01-09 CA CA3049608A patent/CA3049608A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10874670B2 (en) | 2020-12-29 |
| CN110167941B (zh) | 2023-04-04 |
| JP2020504139A (ja) | 2020-02-06 |
| KR20190098266A (ko) | 2019-08-21 |
| EP3567041B1 (en) | 2023-12-27 |
| JP7247092B2 (ja) | 2023-03-28 |
| AU2018206111B2 (en) | 2022-07-21 |
| CN110167941A (zh) | 2019-08-23 |
| EP3567041C0 (en) | 2023-12-27 |
| EP3567041A9 (en) | 2022-04-20 |
| WO2018127195A1 (zh) | 2018-07-12 |
| EP3567041A4 (en) | 2020-08-05 |
| US20190358225A1 (en) | 2019-11-28 |
| EP3567041A1 (en) | 2019-11-13 |
| KR102660196B1 (ko) | 2024-04-24 |
| AU2018206111A1 (en) | 2019-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11345711B2 (en) | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | |
| AU2018206111B2 (en) | Substituted fused heteroaryl compound serving as a kinase inhibitor, and applications thereof | |
| US20250320219A1 (en) | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | |
| AU2020342189B2 (en) | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | |
| US11345710B2 (en) | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | |
| US11547703B2 (en) | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | |
| US20240059695A1 (en) | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | |
| CN114026097B (zh) | 取代的吡唑并喹唑啉酮化合物及其应用 | |
| CN120092008A (zh) | 取代的杂芳基双环化合物作为usp1抑制剂及其应用 | |
| CN114787162B (zh) | 取代的咪唑并喹喔啉化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220817 |